• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Scientific articles
Mar 2024

High-throughput screening of small-molecules libraries identified antibacterials against clinically relevant multidrug-resistant A. baumannii and K. pneumoniae

eBioMedicine

by Blasco B; Jang S; Terauchi H; Kobayashi N; Suzuki S; Akao Y; Ochida A; Morishita N; Takagi T; Nagamiya H; Suzuki Y; Watanabe T; Lee H; Lee S; David Shum D; Cho A; Koh D; Park S; Lee H; Kim K; Ropponen HK; Augusto da Costa RM; Dunn S; Ghosh S; Sjö P; Piddock LJV. eBioMedicine 2024. 102: 105073 doi: 10.1016/j.ebiom.2024.105073

Summary: The World Health Organization has identified the threat posed by drug-resistant gram-negative bacteria as a global health priority. However, the current pipeline for new antibiotics is inadequate; antibacterials with novel mechanisms of action are urgently needed. The authors of this manuscript aimed to identify new chemical entities with activity against multidrug-resistant strains of priority pathogens Klebsiella pneumoniae and Acinetobacter baumannii. They  implemented and validated a primary whole cell screening methodology to test new chemical matter from the proprietary compound collections of three pharmaceutical companies. Two new scaffolds with activity against multidrug-resistant A. baumannii were identified.  This study provides evidence that a screening strategy starting with multidrug-resistant bacteria can be useful for screening new chemical matter.

access the article

Antimicrobial resistance

Latest scientific articles

Loading...
Scientific articles
14 May 2026

In vitro profiling of Trypanosoma cruzi inhibitors identified from high throughput screening and application to parasite painting

International Journal for Parasitology: Drugs and Drug Resistance
Scientific articles
13 May 2026

Chemical genetics reveals Leishmania KKT2 and CRK9 kinase activity is required for cell cycle progression

PLOS Pathogens
Scientific articles
14 May 2026

Mycetoma as a major cause of limb amputation in Northeastern Ethiopia: A facility-based retrospective study

PLOS Neglected Tropical Diseases
Scientific articles
30 Apr 2026

Overcoming Trypanosoma cruzi persistence with a mechanistically distinct drug combination

npj Antimicrobials and Resistance
VIEW ALL

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Youtube X-twitter Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license